小细胞肺癌合并恶性心包积液临床特点及预后因素分析

阳昊; 梅同华

doi:10.13406/j.cnki.cyxb.002880

您当前的位置：

首页 >

文章列表页 >

小细胞肺癌合并恶性心包积液临床特点及预后因素分析

临床研究 | 更新时间：2022-06-24

- 小细胞肺癌合并恶性心包积液临床特点及预后因素分析
- Analysis of prognostic factors and clinical characteristics of patients with small cell lung cancer with malignant pericardial effusion
- 重庆医科大学学报 2022年47卷第5期页码：577-582
- 作者机构：
  
  重庆医科大学附属第一医院呼吸与危重症医学科，重庆　400016
- 作者简介：
  
  阳昊，Email：935148751@qq.com，研究方向：肺癌研究和治疗。
  梅同华，Email：mtonghua@163.com。
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.002880
  中图分类号： R734.2
- 纸质出版日期：2022-05-28，
  
  收稿日期：2020-10-28，
扫描看全文
阳昊, 梅同华. 小细胞肺癌合并恶性心包积液临床特点及预后因素分析[J]. 重庆医科大学学报, 2022,47(5):577-582.

Hao Yang, Tonghua Mei. Analysis of prognostic factors and clinical characteristics of patients with small cell lung cancer with malignant pericardial effusion[J]. Journal of Shanxi Agricultural Sciences, 2022,47(5):577-582.
阳昊, 梅同华. 小细胞肺癌合并恶性心包积液临床特点及预后因素分析[J]. 重庆医科大学学报, 2022,47(5):577-582. DOI： 10.13406/j.cnki.cyxb.002880.

Hao Yang, Tonghua Mei. Analysis of prognostic factors and clinical characteristics of patients with small cell lung cancer with malignant pericardial effusion[J]. Journal of Shanxi Agricultural Sciences, 2022,47(5):577-582. DOI： 10.13406/j.cnki.cyxb.002880.

摘要

目的：

评估小细胞肺癌（small cell lung cancer，SCLC）患者恶性心包积液（malignant pericardial effusion，MPCE）的发生率及其预后的危险因素。

方法：

回顾性分析美国监测、流行病学和最终结果（Surveillance，Epidemiology，and End Results，SEER）数据库中2004年至2015年SCLC患者的临床资料，采用Kaplan-Meier法及log-rank检验比较有无MPCE的总体生存率（overall survival，OS），Cox比例风险模型评估MPCE是否为影响预后的独立危险因素。随后采用单因素和多因素分析研究SCLC伴MPCE患者预后的独立相关因素。

结果：

在74 125例SCLC患者中，1 694例（2.29%）出现MPCE。肿瘤较大且淋巴结分期较高的女性患者发生MPCE的概率较高。相比于没有MPCE组，MPCE患者的OS更差（中位生存时间：3个月vs.7个月；1年OS：16.50% vs.29.53%；2年OS：7.67% vs.13.19%；

0.001）。多因素分析显示，MPCE也是SCLC预后较差的独立因素（

=1.41，95% CI=1.34~1.48；

0.001）。在1 694例SCLC伴MPCE中，多因素分析显示年龄、性别、N分期、放疗、化疗情况是患者预后的独立影响因素。

结论：

伴有MPCE的SCLC患者少见（2.29%），总体生存率较低，诊断年龄较小、女性、N分期较低的患者预后较好，对患者进行放疗、化疗可以显著改善患者预后。

Abstract

Objective

To evaluate the incidence of malignant pericardial effusion (MPCE) and its prognostic risk factors at presentation in patients with small-cell lung cancer (SCLC) .

Methods

This study retrospectively analyzed the clinical data of SCLC patients from the SEER (Surveillance

Epidemiology

and End Results) database between 2004 and 2015. The Kaplan-Meier method and log-rank test were used to estimate the overall survival (OS) and the Cox proportional hazard model was used to assess whether MPCE was an independent risk factor for prognosis. Then we used univariate and multivariate analyses to explore the independent prognostic factors of SCLC with MPCE.

Results

Among the 74 125 patients with SCLC

MPCE was present in 1 694 (2.29%) cases. The probability of MPCE was higher in female patients with larger tumors and higher lymph node stages at presentation. Compared with patients without MPCE

the OS in patients with MPCE was significantly worse (median survival time: 3 months vs.7 months; estimated 1-year OS: 16.50% vs. 29.53%; 2-year OS: 7.67% vs.13.19%;

0.001) . Multivariate analysis showed MPCE was also an independent factor for poor prognosis of SCLC (

=1.41

95% CI=1.34-1.48;

0.001) . In 1 694 cases of SCLC with MPCE

multivariate analysis showed that age

gender

N stage

radiotherapy and chemotherapy were independent prognostic factors.

Conclusion

SCLC patients with MPCE are rare (2.29%) with poor OS

and the patients with younger age at diagnosis

female and lower N stage have a better prognosis. Radiotherapy and chemotherapy can significantly improve the prognosis of the patients.

关键词

肺肿瘤小细胞肺癌恶性心包积液SEER数据库生存率预后

Keywords

lung neoplasmsmall cell lung cancermalignant pericardial effusionSEER databasesurvival rateprognosis

references

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.

Shepherd FA, Crowley J, van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer[J]. J Thorac Oncol, 2007, 2(12): 1067-1077.

van Meerbeeck JP, Fennell DA, de Ruysscher DKM. Small-cell lung cancer[J]. Lancet, 2011, 378(9804): 1741-1755.

Shirasawa M, Fukui T, Kusuhara S, et al. Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer[J]. Cancer Manag Res, 2018, 10: 6039-6047.

Li J, Zhao YS, Li C, et al. The revision of 8th edition TNM stage criteria is more accurate in prediction postoperative survival for SCLC patients[J]. Int J Surg, 2017, 48: 83-85.

Ou SHI, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition[J]. J Thorac Oncol, 2009, 4(3): 300-310.

Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer[J]. J Thorac Oncol, 2007, 2(8): 686-693.

Ou SHI, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23, 583 patients in the California Cancer Registry[J]. J Thorac Oncol, 2008, 3(3): 216-227.

Klatt EC, Heitz DR. Cardiac metastases[J]. Cancer, 1990, 65(6): 1456-1459.

Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease[J]. Prog Cardiovasc Dis, 2010, 53(2): 157-163.

MacGee W. Metastatic and invasive tumours involving the heart in a geriatric population: a necropsy study[J]. Virchows Arch A Pathol Anat Histopathol, 1991, 419(3): 183-189.

Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12, 485 consecutive autopsies[J]. Arch Pathol Lab Med, 1993, 117(10): 1027-1031.

Refaat MM, Katz WE. Neoplastic pericardial effusion[J]. Clin Cardiol, 2011, 34(10): 593-598.

Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion[J]. J Clin Oncol, 2005, 23(22): 5211-5216.

Kim SH, Kwak MH, Park S, et al. Clinical characteristics of malignant pericardial effusion associated with recurrence and survival[J]. Cancer Res Treat, 2010, 42(4): 210-216.

Edoute Y, Malberger E, Kuten A, et al. Symptomatic pericardial effusion in lung cancer patients: the role of fluid cytology[J]. J Surg Oncol, 1990, 45(2): 121-123.

Kato R, Hayashi H, Chiba Y, et al. Prognostic impact of minimal pericardial effusion in patients with advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2017, 18(6): e449-e455.

Niho S, Kubota K, Yoh K, et al. Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis[J]. J Thorac Oncol, 2011, 6(4): 796-800.

陈筱玲, 方健, 聂鋆, 等. 160例老年小细胞肺癌预后多因素分析[J]. 中国肺癌杂志, 2014, 17(1): 15-23.

Chen XL, Fang J, Nie Y, et al. Multivariate analysis of prognostic factors in the eldly patients with small cell lung cancer: a study of 160 patients[J]. Chin J Lung Cancer, 2014, 17(1): 15-23.

Dai CY, Ren YJ, Xie D, et al. Does lymph node metastasis have a negative prognostic impact in patients with NSCLC and M1a disease?[J]. J Thorac Oncol, 2016, 11(10): 1745-1754.

朱慧, 王燕, 周宗玫, 等. 154例广泛期小细胞肺癌治疗结果预后因素分析[J]. 中华放射肿瘤学杂志, 2011, 20(2): 96-99.

Zhu H, Wang Y, Zhou ZM, et al. Prognostic factors for extensive disease small cell lung cancer[J]. Chin J Radiat Oncol, 2011, 20(2): 96-99.

Press OW, Livingston R. Management of malignant pericardial effusion and tamponade[J]. JAMA, 1987, 257(8): 1088-1092.

Okamoto H, Shinkai T, Yamakido M, et al. Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion[J]. Cancer, 1993, 71(1): 93-98.

Karatolios K, Pankuweit S, Moosdorf RG, et al. Vascular endothelial growth factor in malignant and benign pericardial effusion[J]. Clin Cardiol, 2012, 35(6): 377-381.

Lamparter S, Schoppet M, Christ M, et al. Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion[J]. Am J Cardiol, 2005, 95(9): 1065-1069.

Qiu MZ, Shi SM, Chen ZH, et al. Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: a SEER-based study[J]. Cancer Med, 2018, 7(8): 3662-3672.

Nakazawa K, Kurishima K, Tamura T, et al. Specific organ metastases and survival in small cell lung cancer[J]. Oncol Lett, 2012, 4(4): 617-620.

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

倾向性评分匹配评价术后放疗在局限期小细胞肺癌的价值

基于SEER数据库分析142 007例乳腺癌诊断时婚姻状态与预后的关系

前后循环梗死评分系统：1种评估急性缺血性卒中患者预后的新方法

肌肉超声回声联合血浆炎性因子对ICUAW诊断及预后评估的价值研究